Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AKTX

Akari Therapeutics Plc ADR

Dec 12 • 01:16PM ET

1.00

Dollar change +0.02
Percentage change 2.04	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN ALNY NBIX ARGX ADAP FATE CLLS TGTX MCRB VCNX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.40%	Shs Outstand	12.14M	Perf Week	-21.26%
Market Cap	12.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	12.10M	Perf Month	-56.52%
Income	-9.95M	PEG	-	EPS next Q	-	Inst Own	1.49%	Short Float	0.47%	Perf Quarter	-69.28%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	0.56%	Short Ratio	1.53	Perf Half Y	-67.21%
Book/sh	-0.55	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf Year	-67.95%
Cash/sh	0.19	P/C	5.40	EPS next 5Y	-	ROE	-	52W Range	0.90 - 4.40	Perf YTD	-67.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-77.27%	Beta	0.81
Dividend TTM	-	Quick Ratio	0.29	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.11%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	0.29	EPS Y/Y TTM	13.28%	Oper. Margin	-	RSI (14)	29.61	Volatility	15.66% 18.56%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	80.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	87.64%	Payout	-	Rel Volume	1.73	Prev Close	0.98
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 19 AMC	Avg Volume	37.26K	Price	1.00
SMA20	-26.85%	SMA50	-51.19%	SMA200	-59.25%	Trades		Volume	38,703	Change	2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

Nov-19-24 08:00AM	Akari Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) -31.44%
Nov-14-24 04:15PM	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio (GlobeNewswire) -6.73%
Nov-08-24 08:00AM	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger (GlobeNewswire)
Oct-15-24 08:00AM	Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger (GlobeNewswire)
Sep-17-24 08:00AM	Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics (GlobeNewswire)
04:15PM	Loading…
Aug-19-24 04:15PM	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +5.42%
08:00AM	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy (GlobeNewswire)
Jun-05-24 08:00AM	Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders (GlobeNewswire) +9.88%
Jun-04-24 08:00AM	Akari Therapeutics Secures $7.6 Million in Upsized Financing Round (GlobeNewswire) +14.20%
May-16-24 08:00AM	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
May-01-24 08:01AM	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
08:00AM	Loading…
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%
Sep-29-23 08:00AM	Akari Therapeutics Reports First Half 2023 Financial Results and Highlights (GlobeNewswire)
Sep-27-23 08:00AM	Akari Therapeutics to Present at Emerging Growth Conference (GlobeNewswire)
Sep-21-23 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit (GlobeNewswire)
Sep-19-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs (GlobeNewswire)
Sep-05-23 08:00AM	Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.59%
Aug-21-23 02:01PM	British pharma opens U.S. headquarters in Boston (American City Business Journals)
Aug-18-23 08:00AM	Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials (GlobeNewswire) +10.00%
08:00AM	Loading…
Aug-15-23 08:00AM	Akari Therapeutics, Plc Announces ADS Ratio Change (GlobeNewswire) -21.20%
Aug-02-23 08:00AM	Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Aug-01-23 07:30AM	Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely (Simply Wall St.) +7.13%
Jul-27-23 08:00AM	Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire) +7.94%
Jul-19-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer (GlobeNewswire)
Jul-13-23 08:00AM	Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA (GlobeNewswire) +6.15%
Jul-11-23 08:00AM	Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy (GlobeNewswire)
Jul-06-23 08:00AM	Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire)
Jul-05-23 08:00AM	Akari Therapeutics Appoints Industry Veteran Wael Hashad to Board of Directors (GlobeNewswire)
May-16-23 04:05PM	Aspira Womens Health Names Torsten Hombeck as Chief Financial Officer (GlobeNewswire) +12.28%
08:00AM	Akari Therapeutics to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-01-23 08:00AM	Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights (GlobeNewswire)
Apr-25-23 04:15PM	Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement (GlobeNewswire) +6.31%
Apr-19-23 02:01PM	Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m (Simply Wall St.)
Apr-14-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs (GlobeNewswire) +5.26%
Apr-11-23 08:00AM	Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-03-23 08:00AM	Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting (GlobeNewswire) +12.00%
Mar-30-23 09:09AM	Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering (GlobeNewswire) -16.34%
Mar-29-23 08:00AM	Poland and U.K. Regulatory Authorities URPL and MHRA Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study (GlobeNewswire) -5.23%
Feb-21-23 08:00AM	Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings (GlobeNewswire) -10.88%
Feb-15-23 08:00AM	Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) (GlobeNewswire)
Feb-13-23 08:00AM	Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults (GlobeNewswire)
Jan-04-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2023 (GlobeNewswire) +5.09%
Dec-01-22 08:00AM	Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference (GlobeNewswire)
Nov-22-22 08:00AM	Akari Therapeutics to Participate in the Ophthalmology Day at BTIG (GlobeNewswire)
Nov-10-22 08:00AM	Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA (GlobeNewswire) +5.88%
Nov-09-22 08:00AM	Akari Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +8.51%
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
08:00AM	Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer (GlobeNewswire)
Oct-31-22 08:00AM	Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference (GlobeNewswire)
Oct-28-22 04:30PM	Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Sep-27-22 08:00AM	Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Sep-22-22 08:00AM	Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-12-22 08:00AM	Akari Therapeutics Announces $12.75 Million Registered Direct Offering (GlobeNewswire) -27.88%
Sep-08-22 06:48AM	One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year (Simply Wall St.) -9.01%
Aug-01-22 08:00AM	Akari Therapeutics Narrows Pipeline Focus (GlobeNewswire) +5.26%
Jul-29-22 09:36AM	Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely? (Simply Wall St.) +15.42%
Jul-28-22 08:00AM	Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy (GlobeNewswire)
Jul-20-22 06:00AM	Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Jul-07-22 08:00AM	Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) (GlobeNewswire) +9.47%
Jun-13-22 07:00AM	Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies (GlobeNewswire)
May-19-22 04:05PM	Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting (GlobeNewswire) -7.63%
May-16-22 06:00AM	Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress (GlobeNewswire)
May-11-22 07:00AM	Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting (GlobeNewswire) -5.04%
May-10-22 07:00AM	Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology (GlobeNewswire) +5.31%
May-09-22 07:00AM	Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) (GlobeNewswire)
Mar-21-22 08:00AM	Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting (GlobeNewswire)
Mar-09-22 07:30AM	Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch (GlobeNewswire)
Mar-08-22 11:45AM	Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering (GlobeNewswire) -9.69%
Mar-05-22 07:02AM	One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year (Simply Wall St.)
Mar-02-22 07:00AM	Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer (GlobeNewswire)
Feb-28-22 09:12AM	Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma (GlobeNewswire)
Feb-11-22 07:00AM	Akari Therapeutics to Present at BIO CEO & Investor Conference (GlobeNewswire) +9.77%
Jan-26-22 08:30AM	Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases (GlobeNewswire) +5.26%
Jan-19-22 08:30AM	FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies (GlobeNewswire)
Jan-04-22 07:00AM	Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-30-21 11:03AM	Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering (GlobeNewswire) -6.76%
Dec-05-21 06:13AM	We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-03-21 07:45AM	Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Dec-01-21 08:30AM	Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders (GlobeNewswire)
Oct-26-21 08:00AM	Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit (GlobeNewswire)
Oct-25-21 08:30AM	Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program (GlobeNewswire)
Sep-22-21 09:00AM	Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference (GlobeNewswire)
08:30AM	Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Sep-10-21 08:30AM	Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium (GlobeNewswire)
Sep-07-21 07:00AM	Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Jul-07-21 09:15AM	Akari Therapeutics Announces Private Placement (GlobeNewswire)
Jun-29-21 04:01PM	Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Apr-28-21 10:25AM	Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder (Benzinga)
08:00AM	Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid (GlobeNewswire)

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTX

Akari Therapeutics Plc ADR

Upgrade your FINVIZ experience